{"id":4130,"date":"2026-11-04T09:00:00","date_gmt":"2026-11-04T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4130"},"modified":"2026-11-07T16:07:53","modified_gmt":"2026-11-07T20:07:53","slug":"lyell-agrees-80-million-placement-ahead-of-car-t-pivotal-data","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4130","title":{"rendered":"Lyell Agrees $80 Million Placement Ahead of CAR T Pivotal Data"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4140\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Lyell_Immunopharma_Deal_and_Financing.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Lyell Immunopharma<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Private placement ($80 million)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous dual-target CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Ronde-cel (CD19\/CD20); LYL273 (GCC)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19\/CD20; GCC<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Large B-cell lymphoma; colorectal cancer<\/p>\n<h4>Summary<\/h4>\n<p>Previously missed November 4 primary disclosure: Lyell agreed to sell about $80 million of common stock in a private placement to fund pivotal development of dual-target CD19\/CD20 CAR T ronde-cel and its GCC CAR T program. The release anticipated closing on or about November 4; a completed close was not independently confirmed.<\/p>\n<p>The agreement covers 7,428,040 shares at $10.77 per share, the November 3 closing price, with ARCH, Adage, Caligan and RTW among investors. Lyell guides cash runway into 2028, expected pivotal PiNACLE data in mid-2027 and a BLA submission in the second half of 2027. Those are forward plans, not observed outcomes.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> the raise extends the operating runway through a consequential CAR T dataset and reduces near-term financing dependence. Pricing and institutional participation support this. Counterargument: dilution is immediate while efficacy and regulatory acceptance remain uncertain.<\/p>\n<p><strong>Interpretation B:<\/strong> capital may be needed to support expensive pivotal and manufacturing programs rather than signaling de-risked clinical benefit. The two ongoing pivotal studies and large-scale production support this view. Verified close, full pivotal response durability, comparative Phase 3 results, CMC release yields and audited cash burn would discriminate.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Lyell develops ronde-cel, autologous T cells engineered to target CD19 and CD20 on large B-cell lymphoma, and LYL273 targeting GCC in colorectal cancer. Dual antigen targeting aims to reduce antigen escape, but that advantage remains unproven in a randomized comparison.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Gross proceeds are not net cash; the offered $80 million should not be counted as closed until closing evidence.<\/li>\n<li>December ASH data are a future catalyst.<\/li>\n<li>No new efficacy result was announced.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Material financing for a late-stage hematologic cell-therapy program, with the clinical and manufacturing evidence still ahead.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive for financing access; uncertain for product outcome. Confidence in Facts: high for signed terms, moderate for runway. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Previously missed November 4 primary disclosure: Lyell agreed to sell about $80 million of common stock in a private placement to fund pivotal development of dual-target CD19\/CD20 CAR T ronde-cel and its GCC CAR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4140,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1403,1405,1404],"class_list":["post-4130","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-lyell-immunopharma","tag-private-placement","tag-ronde-cel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4130"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4130\/revisions"}],"predecessor-version":[{"id":4152,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4130\/revisions\/4152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4140"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}